Maitreya Medicare Q2 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹85 Cr
- ROE
- -9.34%
- Price to sales
- 2.01
- Debt to equity
- 1.15
- 52W high / low
- ₹289 / ₹108
- Sales growth (5Y)
- -5.59%
- EBITDA margin
- -0.71%
- Net profit margin
- -5.67%
- Promoter holding
- 73.11%
- Sales (last year)
- ₹42 Cr
Incorporated in 2019, Maitreya Medicare Ltd is an integrated multispeciality hospital with primary secondary & tertiary care situated in Surat, Gujrat.[1]
Guidance scorecard · Q2 FY26 call
What Maitreya Medica.'s management guided
and where it ranks in Healthcare Services
RevenueQ2 FY25 call
10–20%- FY25 revenue target is INR 45-50 crores; FY26 target is around INR 60 crores.
- Valsad unit expected to add revenue of INR 1.25 crores initially, potentially growing up to INR 2.5-3 crores/month post-launch (expected Q1 FY25).
- Prannath Hospital revenue currently INR 40-45 lakhs/month, potentially reaching INR 2 crores/month within 2 years.
- Current bed utilization at ~55% (250 beds used out of 555); strategy focuses on increasing utilization to 100% by 2025 to drive organic growth without adding beds immediately.
- OPD utilization is at 50%; plans to increase OPD volumes across units — e.g., Surat handling 100 OPDs/day, Prannath 250/day, Valsad expected 200/day at full operation.
2 more points from Maitreya Medica.'s call on revenue
Create a free account to keep reading this call
MarginsQ2 FY25 call
FlatSee what Maitreya Medica. said on margins — free account, 30 seconds.
CapexQ2 FY25 call
Planned- Installation and operationalization of cath labs at KLS Memorial Hospital and Prannath Hospital, enhancing cardiology and cardiac surgery capabilities.
- Development of a state-of-the-art Valsad hospital with 120 beds expected to be operational by Q1 FY25.
- Expansion in Tulip Agility Private Limited with focus on elderly care and allied health concepts, planning for multi-city growth.
2 more points from Maitreya Medica.'s call on capex
Create a free account to keep reading this call
FundraisingQ2 FY25 call
See what Maitreya Medica. said on fundraising — free account, 30 seconds.
Order bookQ2 FY25 call
Ask what Maitreya Medica. said on the order book →
Full Q2 FY25 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹903 Cr | — | |
| 2 | 40%+ | Flat | ₹583 Cr | 22.2 | |
| 3 | Aster DM Quality Care Ltd | 20–40% | Up 2%+ | ₹58,782 Cr | 162.9 |
| 4 | 20–40% | Up 0–2% | ₹1,730 Cr | 17.5 | |
| 5 | 20–40% | Up 0–2% | ₹580 Cr | 11.9 | |
| 6 | 20–40% | Flat | ₹1.13L Cr | 53.9 |
Sign up free to see every company in the sector ranking and track Maitreya Medica..
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingFinancials of Maitreya Medica.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Maitreya Medica.
Shareholding breakup across reporting periods.
| Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Promoters + | 73.11% | 73.11% | 73.11% | 73.00% | 73.11% | 73.11% |
| FIIs + | 2.53% | 0.41% | 0.01% | 0.00% | 0.00% | 0.00% |
| DIIs + | 1.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public + | 23.02% | 26.48% | 26.88% | 27.00% | 26.89% | 26.89% |
| No. of Shareholders | 474 | 907 | 986 | 978 | 976 | 1,024 |
Pros & Cons
Maitreya Medica.
Key positives and risks surfaced from the company insights section.
- Stock is trading at 3.07 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.59% over past five years.
- Company has a low return on equity of 3.44% over last 3 years.
- Earnings include an other income of Rs.1.13 Cr.
- Stock is trading at 3.07 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.59% over past five years.
- Company has a low return on equity of 3.44% over last 3 years.
- Earnings include an other income of Rs.1.13 Cr.
Financials of Maitreya Medica.
Quarterly Results
Quarter-by-quarter operating performance
Financials of Maitreya Medica.
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 55.93 | 49.35 | 39.28 | 46.08 | 44.98 | 41.96 | 44.83 |
| Expenses + | 48.68 | 45.98 | 32.02 | 40.08 | 40.10 | 42.26 | 44.67 |
| Operating Profit | 7.25 | 3.37 | 7.26 | 6.00 | 4.88 | -0.30 | 0.16 |
| OPM % | 12.96% | 6.83% | 18.48% | 13.02% | 10.85% | -0.71% | 0.36% |
| Other Income + | 0.43 | 0.33 | 0.53 | 0.30 | 0.57 | 0.89 | 1.13 |
| Interest | 0.82 | 0.78 | 0.57 | 0.84 | 0.80 | 1.48 | 2.31 |
| Depreciation | 1.09 | 1.32 | 1.29 | 1.27 | 1.50 | 1.52 | 1.93 |
| Profit before tax | 5.77 | 1.60 | 5.93 | 4.19 | 3.15 | -2.41 | -2.95 |
| Tax % | 26.52% | 28.75% | 28.16% | 29.12% | 42.54% | 2.49% | |
| Net Profit + | 4.24 | 1.14 | 4.25 | 2.97 | 1.82 | -2.47 | -3.37 |
| EPS in Rs | 8.48 | 2.28 | 8.57 | 4.38 | 2.69 | -3.65 | -4.98 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Maitreya Medica.
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 4.96 | 6.78 | 6.78 | 6.78 | 11.46 |
| Reserves | 3.85 | 4.70 | 3.81 | 18.07 | 19.94 | 17.48 | 16.54 |
| Borrowings + | 14.24 | 12.38 | 11.59 | 11.10 | 10.53 | 27.90 | 23.90 |
| Other Liabilities + | 7.17 | 7.40 | 8.55 | 7.91 | 10.75 | 16.28 | 16.54 |
| Total Liabilities | 25.27 | 24.49 | 28.91 | 43.86 | 48.00 | 68.44 | 68.44 |
| Fixed Assets + | 13.84 | 13.40 | 11.60 | 14.32 | 15.26 | 40.81 | 40.77 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.07 | 0.32 | 0.68 | 1.47 | 0.04 | 0.05 | 0.04 |
| Other Assets + | 10.36 | 10.77 | 16.63 | 28.07 | 32.70 | 27.58 | 27.63 |
| Total Assets | 25.27 | 24.49 | 28.91 | 43.86 | 48.00 | 68.44 | 68.44 |
Financials of Maitreya Medica.
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4.45 | 0.08 | 2.59 | -2.50 | 5.06 | 8.06 |
| Cash from Investing Activity + | -5.07 | -0.02 | 0.36 | -5.44 | -7.37 | -26.74 |
| Cash from Financing Activity + | 2.16 | -1.86 | -1.59 | 12.21 | 3.67 | 19.04 |
| Net Cash Flow | 1.55 | -1.80 | 1.36 | 4.27 | 1.36 | 0.36 |
| Free Cash Flow | -1.17 | -0.82 | 3.16 | -4.11 | 2.68 | -19.02 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 77% | 54% | 40% | -12% | 134% | -2,727% |
Financials of Maitreya Medica.
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 31.91 | 43.42 | 90.41 | 108.52 | 121.40 | 95.86 |
| Inventory Days | 68.78 | 40.82 | 69.86 | 40.26 | 36.56 | 63.48 |
| Days Payable | 258.06 | 221.84 | 319.59 | 207.25 | 199.54 | 303.03 |
| Cash Conversion Cycle | -157.37 | -137.61 | -159.32 | -58.47 | -41.58 | -143.69 |
| Working Capital Days | -4.11 | 3.11 | 43.12 | 73.43 | 73.68 | -11.05 |
| ROCE % | 12.33% | 32.85% | 17.30% | 10.60% | -1.85% |
Guidance history
How Maitreya Medica.'s guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY25 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY24 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Maitreya Medica.'s management said in earlier quarters
Others in Healthcare Services this season
- Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio